vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and STAG Industrial, Inc. (STAG). Click either name above to swap in a different company.
STAG Industrial, Inc. is the larger business by last-quarter revenue ($224.2M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). STAG Industrial, Inc. runs the higher net margin — 27.6% vs 13.3%, a 14.3% gap on every dollar of revenue. On growth, STAG Industrial, Inc. posted the faster year-over-year revenue change (9.1% vs -1.8%). Over the past eight quarters, STAG Industrial, Inc.'s revenue compounded faster (8.7% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Stag Arms is a firearms manufacturer founded in May 2003 and located in Cheyenne, Wyoming. Stag Arms is a manufacturer of the AR-15 type rifle, marketed as Stag-15 rifles. Stag advertises that all their weapons and accessories are made in the United States. They are best known for their left-handed AR-15 rifles, which use a mirror imaged upper receiver and have the ejection port reversed for left-handed shooters and the safety selector control on the right side of the lower receiver.
AMPH vs STAG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $224.2M |
| Net Profit | $24.4M | $62.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 27.6% |
| Revenue YoY | -1.8% | 9.1% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $224.2M | ||
| Q4 25 | $183.1M | $220.9M | ||
| Q3 25 | $191.8M | $211.1M | ||
| Q2 25 | $174.4M | $207.6M | ||
| Q1 25 | $170.5M | $205.6M | ||
| Q4 24 | $186.5M | $199.3M | ||
| Q3 24 | $191.2M | $190.7M | ||
| Q2 24 | $182.4M | $189.8M |
| Q1 26 | — | $62.0M | ||
| Q4 25 | $24.4M | $83.5M | ||
| Q3 25 | $17.4M | $48.6M | ||
| Q2 25 | $31.0M | $50.0M | ||
| Q1 25 | $25.3M | $91.4M | ||
| Q4 24 | $38.0M | $51.0M | ||
| Q3 24 | $40.4M | $41.9M | ||
| Q2 24 | $37.9M | $59.8M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | — |
| Q1 26 | — | 27.6% | ||
| Q4 25 | 13.3% | 37.8% | ||
| Q3 25 | 9.0% | 23.0% | ||
| Q2 25 | 17.8% | 24.1% | ||
| Q1 25 | 14.8% | 44.5% | ||
| Q4 24 | 20.4% | 25.6% | ||
| Q3 24 | 21.1% | 21.9% | ||
| Q2 24 | 20.8% | 31.5% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $8.9M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $3.6B |
| Total Assets | $1.6B | $7.2B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $8.9M | ||
| Q4 25 | $282.8M | $14.9M | ||
| Q3 25 | $276.2M | $17.3M | ||
| Q2 25 | $231.8M | $15.4M | ||
| Q1 25 | $236.9M | $9.3M | ||
| Q4 24 | $221.6M | $36.3M | ||
| Q3 24 | $250.5M | $70.0M | ||
| Q2 24 | $217.8M | $33.3M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $3.3B | ||
| Q3 25 | $608.6M | $3.1B | ||
| Q2 25 | $607.7M | $3.0B | ||
| Q1 25 | $603.9M | $3.0B | ||
| Q4 24 | $601.6M | $3.0B | ||
| Q3 24 | $596.4M | $2.9B | ||
| Q2 24 | $586.9M | $2.8B |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $788.8M | $3.6B | ||
| Q3 25 | $776.7M | $3.4B | ||
| Q2 25 | $757.5M | $3.4B | ||
| Q1 25 | $751.3M | $3.5B | ||
| Q4 24 | $732.3M | $3.5B | ||
| Q3 24 | $727.7M | $3.3B | ||
| Q2 24 | $713.3M | $3.3B |
| Q1 26 | — | $7.2B | ||
| Q4 25 | $1.6B | $7.2B | ||
| Q3 25 | $1.7B | $6.9B | ||
| Q2 25 | $1.6B | $6.8B | ||
| Q1 25 | $1.6B | $6.8B | ||
| Q4 24 | $1.6B | $6.8B | ||
| Q3 24 | $1.5B | $6.6B | ||
| Q2 24 | $1.5B | $6.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 0.91× | ||
| Q3 25 | 0.78× | 0.91× | ||
| Q2 25 | 0.80× | 0.88× | ||
| Q1 25 | 0.80× | 0.87× | ||
| Q4 24 | 0.82× | 0.88× | ||
| Q3 24 | 0.82× | 0.89× | ||
| Q2 24 | 0.82× | 0.84× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | 3.9% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $104.5M | ||
| Q3 25 | $52.6M | $143.5M | ||
| Q2 25 | $35.6M | $111.9M | ||
| Q1 25 | $35.1M | $103.5M | ||
| Q4 24 | $29.0M | $104.9M | ||
| Q3 24 | $60.0M | $128.0M | ||
| Q2 24 | $69.1M | $122.2M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $43.8M | ||
| Q3 25 | $47.2M | $95.5M | ||
| Q2 25 | $25.0M | $62.3M | ||
| Q1 25 | $24.4M | $57.2M | ||
| Q4 24 | $16.6M | $37.6M | ||
| Q3 24 | $46.2M | $86.7M | ||
| Q2 24 | $63.1M | $105.0M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 19.8% | ||
| Q3 25 | 24.6% | 45.2% | ||
| Q2 25 | 14.3% | 30.0% | ||
| Q1 25 | 14.3% | 27.8% | ||
| Q4 24 | 8.9% | 18.8% | ||
| Q3 24 | 24.1% | 45.5% | ||
| Q2 24 | 34.6% | 55.3% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 4.5% | 27.4% | ||
| Q3 25 | 2.8% | 22.7% | ||
| Q2 25 | 6.1% | 23.9% | ||
| Q1 25 | 6.3% | 22.5% | ||
| Q4 24 | 6.7% | 33.8% | ||
| Q3 24 | 7.2% | 21.6% | ||
| Q2 24 | 3.3% | 9.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 1.25× | ||
| Q3 25 | 3.03× | 2.95× | ||
| Q2 25 | 1.15× | 2.24× | ||
| Q1 25 | 1.39× | 1.13× | ||
| Q4 24 | 0.76× | 2.06× | ||
| Q3 24 | 1.48× | 3.06× | ||
| Q2 24 | 1.82× | 2.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
STAG
Segment breakdown not available.
